TransMedics Group, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - TMDX

NEW YORK, NY / ACCESSWIRE / November 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of TransMedics Group, Inc. ("TransMedics Group, Inc.") (NASDAQ:TMDX) concerning possible violations of federal securities laws.

On October 28, 2024, TransMedics reported disappointing financial results for the third quarter of 2024, missing analyst expectations on both the top and bottom lines. Specifically, the Company reported earnings per share ("EPS") of $0.12, missing EPS expectations of $0.29 by nearly 60%. TransMedics also reported revenue of $108.8 million, falling short of analysts ' $115 million estimate.

Following this news, TransMedics stock dropped over 24% in after-hours trading. To obtain additional information, go to:

https://zlk.com/pslra-1/transmedics-group-inc-lawsuit-submission-form?prid=110281&wire=1

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212)363-7500.

WHY LEVI & KORSINSKY:Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services ' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212)363-7500
Fax: (212)363-7171
https://zlk.com/

SOURCE:Levi & Korsinsky, LLP

View the original press release on accesswire.com

© 2024 Accesswire. All Rights Reserved.